Context Therapeutics Inc. — Director's Dealing 2022

Feb 25, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Context Therapeutics Inc. (CNTX)
CIK: 0001842952
Period of Report: 2022-02-25

Reporting Person: Minai-Azary Jennifer Lynn (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-25	Stock Option (right to buy)	$1.79	A	112470	Acquired	2032-02-24	Common Stock (112470.0)	Direct

Footnotes

F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 25, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.